Table 1 Baseline characteristics of the ACTHIVE-001 study cohort

From: HIV-1 envelope trimer vaccine induces sex-associated differences in antibody responses: a phase 1 clinical trial

Per vaccine group

Per sexa

Age group (years)

Full dose (N = 13)

Fx dose

(N = 11)

Age group (years)

Female

(N = 14)

Male

(N = 10)

18–25, n (%)

≥26–30, n (%)

≥31–50, n (%)

Median per vaccine group

4 (31)

6 (46)

3 (23)

29

3 (27)

3 (27)

5 (46)

29

18–25, n (%)

≥26–30, n (%)

≥ 31–50, n (%)

Median per sex

6 (43)

6 (43)

2 (14)

26

1 (10)

3 (30)

6 (60)

32

Sexa

Vaccine group

Female, n (%)

Male, n (%)

7 (54)

6 (46)

7 (64)

4 (36)

Full dose, n (%)

Fx dose, n (%)

7 (50)

7 (50)

6 (60)

4 (40)

Body-mass index (kg/m²)

Body-mass index (kg/m²)

17–25, n (%)

≥ 26–30, n (%)

Median per vaccine group

9 (69)

4 (31)

24.3

9 (82)

2 (8)

22.0

17–25, n (%)

≥ 26–30, n (%)

Median per sex

12 (86)

2 (14)

21.8

6 (60)

4 (40)

24.7

  1. Data are calculated for the modified intention-to-treat cohort, which includes participants who received at least one scheduled vaccination (N = 24). % = Percentage of participants in each category, i.e., 100 × n/N.
  2. aSex at birth. One participant in the full dose group was male at birth, has undergone gender-affirming surgery and currently uses feminising hormone therapy. Fx dose = fractional dose.
Back to article page